GXP in Research and Development

Improving both product and process understanding, in combination with quality risk management, will support the establishment of an appropriate control strategy for consistent product quality and improved process performance

GxP Compliance in R&D

The areas of Research and Development were in the past excluded from the “compliance infrastructure” traditionally applied to the GMP-compliant manufacturing and control operations.

However, the FDA’s ‘risk-based-approach’ initiative and, later, the guidelines that emerged from that initiative: ICH Q8, Q9, Q10, Process Analytical Technology (PAT)… brought the requirement for the application of GxP principles (GLP, GMP, GCP) to the entire Lifecycle of a pharmaceutical product in a much higher level.

Concepts such as Quality by Design (QbD) are applied since the initial stages of development. The application of solid scientific criteria for the evaluation of results and data or the design of experiments, contribute to the knowledge and understanding of the product and the process, which is the key for obtaining and demonstrating the necessary control on the process and its design and the consistent quality of the product.

Quality by Design

The manufacturing process, before its transfer to the production plant, it must be thoroughly understood, including the Critical Process Parameters (CPP). This knowledge provides the ability to make improvements within what is considered the Design Space without potentially affecting product quality. Consequently, an optimization of the process is achieved without the need for revalidation or regulatory approval.

During the development phases of drugs, products used in clinical trials must be manufactured with quality standards equivalent to those applied in commercial drugs, adapting some requirements to the development phases. The labelling and secondary packaging of clinical trial medication is an essential part of the process to ensure that volunteers or designated patients take assigned medication..

R&D Projects

Rephine has experience within the following GxP  related services associated within Research and Development:

  • Risk analysis during development, scaling and process validation
  • ICH Q8 development models
  • Preparation of GXP regulatory inspections (GLP, GMP, GCP)
  • Process Analytical Technology (PAT)
  • Development reports
  • Expert reports
  • GMP in Pharmaceutical Development
  • Support in labeling and distribution of medication for Clinical Trials
  • Internal audits in the Pharmaceutical Development areas
  • Review of Drug dossiers for Registration (DMF, CTD)
GxP Consultancy

Where do you Need our Help?

For GMP Auditing, Quality Assurance & Digitalisation, we’re the partner of choice for all the stakeholders we deal with.

We provide extensive GMP consulting services to help keep our clients ahead of the needs and expectations of regulators.

REPHINE AUDIT GREEN GAP ANALYSIS ICON

Global Audit Library

Explore our extensive GMP audit library to see the range and scope of live reports we have in stock, join a live audit, or commission a bespoke audit

REPHINE AUDIT GREEN AUDIT REPORT LIBRARY ICON

GMP Audit Services

Maintain high standards of life sciences manufacturing supplier qualifications and GMP auditing within the supply chain through our expertise

REPHINE AUDIT BLUE INOVATION CONVOS ICON

GxP Consultancy

Discover how we can help your product reach to market, fully and demonstrably complying with the latest GxP standards

REPHINE DIGITALISATION PURP POST SUBM LIFECYCLE ICON

Digitalisation

From data integrity to implementing new systems, our experienced team with a digital mindset, can lead you to transformative achievements

Related Resources

Close up of nurse holding and typing on tablet CSV

Data Integrity Remediation: A Practical Framework for Pharma

Turn data integrity findings into a sustainable, risk based remediation plan. A practical 7 phase framework for pharma labs.
Read More
csv blog header jan 25 Article

GDP Transport Validation: A Practical Guide for Pharmaceutical Companies

Transport validation is a regulatory requirement under EU GMP Annex 15, yet many pharmaceutical companies still struggle with route selection and risk assessment. This guide ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan CSV

Validation in the New Pharma Reality: Compliance, Digitalisation and AI Under Rising Regulatory Pressure

Watch our webinar with Rephine and ValGenesis on modern, inspection-ready validation: what EU GMP Annex 11 and ALCOA+ now expect, and where AI fits in ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan CSV

Building Inspection-Ready Validation for a Digital, AI-Enabled World

Now watching on-demand: Rephine and ValGenesis on modern, inspection-ready validation, where AI helps in GxP, and what EU GMP Annex 11 and ALCOA+ really expect.
Read More
SAP PALEX CSV Case Study Header Image (1500 x 844 px) Article

Digital Solution Selection in Regulated Environments: Beyond Software Features

Feature lists do not guarantee a successful digital transformation. Discover why a structured, business-led selection process is the real driver of compliance, adoption and long-term ...
Read More
QMS IMP Header image case study May 25 Article

Veterinary GMP in Europe: New Dedicated Framework & VICH GL60 Guide

The EU veterinary sector enters a new era on 16 July 2026. Dedicated GMP regulations replace EudraLex Volume 4 for veterinary products. Learn what changes ...
Read More
GSPR MedTech guide header image .png Article

MDR & IVDR Compliance: A Strategic Approach for MedTech

Regulatory compliance under MDR and IVDR has moved beyond documentation to become a strategic discipline that shapes every stage of a medical device's lifecycle. This ...
Read More
GSPR MedTech guide header image Medical Device

MDR & IVDR Compliance as a Business Outcome

Rephine's 2026 White Paper on MDR & IVDR compliance: strategic guidance for MedTech companies to reduce regulatory risk, avoid delays, and reach the EU market ...
Read More
mock inspection blog header Case Study

Full GMP Internal Audit Program Executed On Time

A pharmaceutical manufacturer needed to complete their annual EU GMP internal audit cycle across 11 departments, without the internal capacity to do it. See how ...
Read More

Let's get in touch

Please get in touch. Our expert GMP audit team is only a click away, on standby to answer all your questions.
Social: Linkedin

REPHINE HQ

REPHINE BARCELONA S.L.U

  • Barcelona, Spain                               
  • +34 934 178065

REPHINE CHINA

  • Shanghai, China 

REPHINE INDIA

  • Hyderabad, India                               

Contact Us

Strengthen Your Assurance Journey

GMP Chapter 22 Adapting to Hybrid Documentation Standards